Cargando…

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study

SIMPLE SUMMARY: The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evaluate the real-life pattern of use, efficacy, and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Jeffrey Sum-Lung, Dong, Yawen, Tang, Vikki, Leung, Thomas, Yeung, Cynthia S. Y., Tai, Anna, Law, Ada, Shum, Tracy, Kwok, Gerry Gin-Wai, Li, Bryan Cho-Wing, Leung, Roland, Chiu, Joanne, Ma, Ka-Wing, She, Wong-Hoi, Tsang, Josephine, Cheung, Tan-To, Yau, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122581/
https://www.ncbi.nlm.nih.gov/pubmed/33919277
http://dx.doi.org/10.3390/cancers13092002
_version_ 1783692656771072000
author Wong, Jeffrey Sum-Lung
Dong, Yawen
Tang, Vikki
Leung, Thomas
Yeung, Cynthia S. Y.
Tai, Anna
Law, Ada
Shum, Tracy
Kwok, Gerry Gin-Wai
Li, Bryan Cho-Wing
Leung, Roland
Chiu, Joanne
Ma, Ka-Wing
She, Wong-Hoi
Tsang, Josephine
Cheung, Tan-To
Yau, Thomas
author_facet Wong, Jeffrey Sum-Lung
Dong, Yawen
Tang, Vikki
Leung, Thomas
Yeung, Cynthia S. Y.
Tai, Anna
Law, Ada
Shum, Tracy
Kwok, Gerry Gin-Wai
Li, Bryan Cho-Wing
Leung, Roland
Chiu, Joanne
Ma, Ka-Wing
She, Wong-Hoi
Tsang, Josephine
Cheung, Tan-To
Yau, Thomas
author_sort Wong, Jeffrey Sum-Lung
collection PubMed
description SIMPLE SUMMARY: The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evaluate the real-life pattern of use, efficacy, and safety of cabozantinib in aHCC patients in a territory-wide study. In single-agent cabozantinib patients (n = 27), we found that 3.7% had a response, 44.4% had disease control, and the median overall survival (OS) was 8.28 months. Around 74.1% of patients had adverse events (AEs). We also did an exploratory analysis of patients who received cabozantinib as an add-on to immune-checkpoint inhibitors (ICIs) after progression on ICIs. Out of 15 such patients, 6.7% had a response and the median OS was 15.1 months, with 73.3% of patients having AEs. Overall, cabozantinib had good efficacy, survival, and safety in aHCC patients in a real-life setting. ABSTRACT: (1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients.
format Online
Article
Text
id pubmed-8122581
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81225812021-05-16 The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study Wong, Jeffrey Sum-Lung Dong, Yawen Tang, Vikki Leung, Thomas Yeung, Cynthia S. Y. Tai, Anna Law, Ada Shum, Tracy Kwok, Gerry Gin-Wai Li, Bryan Cho-Wing Leung, Roland Chiu, Joanne Ma, Ka-Wing She, Wong-Hoi Tsang, Josephine Cheung, Tan-To Yau, Thomas Cancers (Basel) Article SIMPLE SUMMARY: The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evaluate the real-life pattern of use, efficacy, and safety of cabozantinib in aHCC patients in a territory-wide study. In single-agent cabozantinib patients (n = 27), we found that 3.7% had a response, 44.4% had disease control, and the median overall survival (OS) was 8.28 months. Around 74.1% of patients had adverse events (AEs). We also did an exploratory analysis of patients who received cabozantinib as an add-on to immune-checkpoint inhibitors (ICIs) after progression on ICIs. Out of 15 such patients, 6.7% had a response and the median OS was 15.1 months, with 73.3% of patients having AEs. Overall, cabozantinib had good efficacy, survival, and safety in aHCC patients in a real-life setting. ABSTRACT: (1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients. MDPI 2021-04-21 /pmc/articles/PMC8122581/ /pubmed/33919277 http://dx.doi.org/10.3390/cancers13092002 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wong, Jeffrey Sum-Lung
Dong, Yawen
Tang, Vikki
Leung, Thomas
Yeung, Cynthia S. Y.
Tai, Anna
Law, Ada
Shum, Tracy
Kwok, Gerry Gin-Wai
Li, Bryan Cho-Wing
Leung, Roland
Chiu, Joanne
Ma, Ka-Wing
She, Wong-Hoi
Tsang, Josephine
Cheung, Tan-To
Yau, Thomas
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
title The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
title_full The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
title_fullStr The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
title_full_unstemmed The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
title_short The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
title_sort use of cabozantinib in advanced hepatocellular carcinoma in hong kong—a territory-wide cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122581/
https://www.ncbi.nlm.nih.gov/pubmed/33919277
http://dx.doi.org/10.3390/cancers13092002
work_keys_str_mv AT wongjeffreysumlung theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT dongyawen theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT tangvikki theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT leungthomas theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT yeungcynthiasy theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT taianna theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT lawada theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT shumtracy theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT kwokgerryginwai theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT libryanchowing theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT leungroland theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT chiujoanne theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT makawing theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT shewonghoi theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT tsangjosephine theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT cheungtanto theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT yauthomas theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT wongjeffreysumlung useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT dongyawen useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT tangvikki useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT leungthomas useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT yeungcynthiasy useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT taianna useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT lawada useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT shumtracy useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT kwokgerryginwai useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT libryanchowing useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT leungroland useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT chiujoanne useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT makawing useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT shewonghoi useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT tsangjosephine useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT cheungtanto useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy
AT yauthomas useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy